Kairos Pharma, Ltd.
KAPAHealthcare|Biotechnology|US
$0.49
+0.03 (+7.33%)
DCF Value
$1.64
Tangible Book / Share
$1.37
Cash / Share
$0.86
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05534646 Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc | Castration-resistant Prostate Cancer | P2 | Recruiting | 116 | RCT, Open-label | AR Blockade, Carotuximab |
| NCT05341947 Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma | Recurrent Glioblastoma | P1 | Withdrawn | — | Open-label | Activated T cells |